Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Titre officiel

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Sommaire:

Cette étude prospective porte sur l'évolution de la maladie chez les patients atteints d'un cancer colorectal qui s'est propagé au foie. Le but de cette étude est de découvrir des biomarqueurs de récidive de la maladie ainsi que des cibles thérapeutiques pour l’établissement du pronostic.

Description de l'essai

Primary Outcome:

  • Utilization rates of characterized genomic and epigenetic features associated with chemotherapy resistance and tumour recurrence in clinical environments
Secondary Outcome:
  • Identification of epigenetic profiles of recurring tumour clones through serial DNA characterization on the NGS platform
  • Identification of epigenetic profiles of recurring tumour clones through serial RNA characterization on the NGS platform
  • Identification of DNA methylation profiles of recurring tumour clones through serial methylome analysis via MethylSeq
  • Non-invasive detection of cfDNA methylation profiles by performing ultra-deep targeted NGS on blood samples
  • Non-invasive detection of cfDNA methylation profiles by performing cfMeDIP-seq on blood samples
Colorectal cancer (CRC), the 2nd leading cause of cancer mortality, often has a pattern of targeting the liver during initial metastases. The Comprehensive Genomic Profiling of Colorectal Cancer Patients with Isolated Liver Metastases to Understand Response and Resistance to Cancer Therapy (COMPARISON) study aims to assess the disease course of CRC by collecting primary tumour and metastatic liver specimens following pre-operative chemotherapy. If relapse occurs following surgical resection of the liver, biopsies will also be done for molecular analysis. As a result, these samples can be analyzed for chemotherapy resistance mechanisms and therapeutic targets to determine potential clinical outcomes for this particular subset of CRC patients.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer